Navigation Links
A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs

Twenty leading US research institutions, patient advocates and biomedical industry release report on the benefits of NIH funding through the 2009 Recovery and Reinvestment Act

WASHINGTON, Jan. 20 /PRNewswire-USNewswire/ -- In advance of the one-year anniversary of the Recovery and Reinvestment Act's enactment on February 17, twenty of the nation's leading research institutions, patient advocates and biomedical industry have released a detailed report on how Recovery Act funding of medical research through the National Institutes of Health (NIH) is at work across the country in the service of better health and a healthier economy.

The new report, Investing in Recovery and Discovery by United for Medical Research (UMR), documents how the $10.5 billion infusion in 2009 and 2010 has come at a propitious time for both the US economy and the nation's biomedical research enterprise.  

The investment is creating and preserving jobs, laying the foundation for industry growth, and helping to reduce long-term health care costs.  The NIH estimates that the funding is saving or preserving 50,000 jobs in research institutions and organizations around the country.  But the full value of the investment is far greater.  Dr. Steve Fluharty is Vice Provost for Research at the University of Pennsylvania, which is a member of UMR, and which received $169 million in stimulus funds for biomedical research.  He explains, "When it comes to NIH stimulus funding, we are truly talking about recovery and reinvestment.  The impact goes beyond the lab and into the companies that supply many of the 325,000 NIH-funded researchers across the country with the tools, technology and resources they need.  Further, NIH grantees generate many of the discoveries the nation's most significant employers – the biotech and pharmaceutical industries – build upon to create the next generation of treatments and cures."  

At the same time, the investment is also forging new areas of science, many of which could not have been pursued just ten years ago, and others which could have been neglected without ARRA.  "We now have the unique opportunity to explore exciting new fields of science that may fundamentally impact our understanding of diseases, and help to tailor treatments with more precision to address the unique needs of very different patients," says Dr. Clyde Yancy, President of the American Heart Association, a UMR member organization.  "The ARRA infusion was more than a stimulus; it has been a catalyst that now provides the opportunity to jumpstart the pace of scientific discovery and ultimately to effect major advances in the quality of health for the American population."  

Investing in Recovery and Discovery illustrates all of these benefits through real-life stories of research scientists and their Recovery Act-funded work.  The report also notes how such scientific and economic advancements could be slowed or neglected if federal funding for NIH were to fall back to pre-Recovery Act levels in 2011 and beyond.  

Janet Lambert, Vice President for Government Relations for biotech company Life Technologies, is UMR's Executive Board Chair and led the crafting of the report.  As she sums it up, "the stimulus infusion is demonstrating that reinvesting in innovative biomedical ideas through the NIH can help the nation achieve better health and a stronger economy.  How much we commit to NIH over time in large measure will determine our success."  

To download the full report, visit  To learn more about UMR, visit,

Members of United for Medical Research include: The American Cancer Society Cancer Action Network; The American Diabetes Association; The American Heart Association; The Association of American Universities; The Association of Independent Research Institutes; The Association of Public and Land-grant Universities; Biotechnology Industry Organization (BIO); Emory University; The Endocrine Society; Genentech; Harvard University; Johns Hopkins University; Life Technologies; National Alliance for Eye and Vision Research; The National Health Council; The University of Pennsylvania; The Pharmaceutical Research and Manufacturers of America (PhRMA); Stanford University; University of Southern California; Washington University in St. Louis.

SOURCE United for Medical Research



SOURCE United for Medical Research
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
2. Life Science Organizations Participate in Economic Recovery by Purchasing Late-Model Lab Equipment
3. Senator Arlen Specter and Richard Gephardt Headline Policy Forum on U.S. Medical Innovation, Highlight Achieving Recovery Through Discovery
4. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
5. SRNLs microbes useful for for environmental cleanup and oil recovery
6. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
7. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
8. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
9. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
10. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
11. Successful Stem Cell Therapy for Treatment of Eye Disease
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , Chief ... Annual Healthcare Conference in New York City , ... p.m. GMT). --> SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> Shire plc ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... , October 27, 2015 ... Automated Semantic Gaze Mapping technology (ASGM) automatically maps data ... Eye Tracking Glasses , so that they can ... --> Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ...
Breaking Biology News(10 mins):